#1 Clinical Trials Search in Europe

Tiotropium Bromide Monohydrate

This article delves into the use of Tiotropium Bromide Monohydrate in clinical trials, focusing on its potential benefits for respiratory conditions. Tiotropium Bromide Monohydrate is a long-acting bronchodilator that has been studied in various formulations and delivery devices. These trials aim to evaluate its effectiveness, absorption, and impact on patients’ quality of life, particularly in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Table of Contents

What is Tiotropium Bromide Monohydrate?

Tiotropium Bromide Monohydrate is a medication that belongs to a class of drugs called long-acting muscarinic antagonists (LAMAs). It is primarily used to treat respiratory conditions by helping to relax and open the airways in the lungs[1]. This medication is also known by its brand names, which include Spiriva HandiHaler and Spiriva Respimat[2].

What Conditions Does Tiotropium Treat?

Tiotropium Bromide Monohydrate is primarily used to treat the following conditions:

  • Chronic Obstructive Pulmonary Disease (COPD): This is a group of lung diseases that includes chronic bronchitis and emphysema, characterized by airflow blockage and breathing-related problems[5].
  • Asthma: While not its primary use, some studies have explored the effectiveness of tiotropium in managing allergic asthma[4].

These conditions can significantly impact a patient’s quality of life, and tiotropium is designed to help manage symptoms and improve breathing.

How is Tiotropium Administered?

Tiotropium Bromide Monohydrate is administered through inhalation. There are several devices used to deliver the medication:

  • Easyhaler: This is a dry powder inhaler that delivers tiotropium in doses of 10 micrograms[1].
  • HandiHaler: This device uses capsules containing 18 micrograms of tiotropium[2].
  • Respimat: This is a soft mist inhaler that delivers 2.5 micrograms of tiotropium per puff, with patients typically taking two puffs for a total dose of 5 micrograms[4].

The medication is usually taken once daily, which helps improve patient adherence to the treatment regimen[5].

Clinical Studies on Tiotropium

Several clinical studies have been conducted to evaluate the effectiveness and safety of Tiotropium Bromide Monohydrate:

  • Pharmacokinetic Studies: These studies compare how the body absorbs and processes tiotropium from different inhaler devices. They measure factors like peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) to understand how quickly and effectively the medication enters the bloodstream[1][2][3].
  • Efficacy Studies: Some studies have looked at how well tiotropium works against specific symptoms. For example, one study examined its effectiveness against allergen-induced early asthmatic responses in individuals with atopic asthma[4].
  • Observational Studies: These studies observe how adherence to tiotropium treatment affects patients’ health-related quality of life and COPD symptoms over time[5].

Effectiveness of Tiotropium

The effectiveness of Tiotropium Bromide Monohydrate is measured in several ways:

  • Lung Function: Tiotropium helps improve lung function by relaxing the airways, which is typically measured through tests like FEV1 (Forced Expiratory Volume in 1 second)[4].
  • Quality of Life: Studies have used questionnaires like the Clinical COPD Questionnaire (CCQ) to assess how tiotropium impacts patients’ overall health status and quality of life[5].
  • Exacerbations: Tiotropium has been shown to reduce the frequency of COPD exacerbations, which are sudden worsening of COPD symptoms[5].
  • Asthma Control: In asthma studies, tiotropium has shown potential in controlling allergen-induced asthmatic responses[4].

Potential Side Effects and Considerations

While Tiotropium Bromide Monohydrate is generally well-tolerated, it’s important to be aware of potential side effects and considerations:

  • Common Side Effects: These may include dry mouth, constipation, and upper respiratory tract infections.
  • Adherence: The effectiveness of tiotropium depends on regular use. Studies have looked at reasons for non-adherence to help improve patient compliance[5].
  • Interactions: Always inform your healthcare provider about all medications you’re taking to avoid potential drug interactions.
  • Proper Use: It’s crucial to use the inhaler device correctly. Your healthcare provider or pharmacist can demonstrate the proper technique.

As with any medication, it’s important to discuss the benefits and potential risks of Tiotropium Bromide Monohydrate with your healthcare provider to determine if it’s the right treatment for your specific condition.

Aspect Details
Study Types Pharmacokinetic, efficacy, and observational studies
Delivery Devices Easyhaler, HandiHaler, Respimat
Dosages Varying from 10 μg to 18 μg per dose
Primary Outcomes Peak plasma concentration, area under the curve, time to peak concentration
Secondary Outcomes Effects on lung function, quality of life, COPD exacerbations
Study Populations Healthy volunteers, COPD patients, asthma patients
Study Durations Range from several days to 13 months
Comparisons Between different Easyhaler variants and Spiriva HandiHaler

FAQ

  • What is Tiotropium Bromide Monohydrate? Tiotropium Bromide Monohydrate is a long-acting bronchodilator medication used to treat respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. It works by relaxing and opening the airways, making it easier to breathe.
  • What types of inhalers are used to deliver Tiotropium Bromide Monohydrate? The clinical trials mentioned in this article study various inhaler types for delivering Tiotropium Bromide Monohydrate, including the Easyhaler, Respimat inhaler, and HandiHaler device. Each device has its own unique features and may deliver different doses of the medication.
  • What are the main outcomes measured in these clinical trials? The main outcomes measured in these trials include the peak plasma concentration of tiotropium, the area under the concentration-time curve, time to reach peak concentration, and the drug's effects on lung function. Some studies also assess the medication's impact on quality of life and the frequency of COPD exacerbations.
  • Are these clinical trials only for patients with respiratory conditions? While some trials focus on patients with COPD or asthma, several of the studies mentioned are conducted on healthy volunteers. This helps researchers understand how the medication is absorbed and processed in the body without the influence of underlying health conditions.
  • How long do these clinical trials typically last? The duration of these clinical trials varies. Some pharmacokinetic studies last for a few days to weeks, while observational studies on the effects of long-term use can last up to 13 months. The exact duration depends on the specific goals and design of each study.

Ongoing Clinical Trials on Tiotropium Bromide Monohydrate

  • Study on Tiotropium for Preventing Severe Asthma Attacks in Preschool Children with Uncontrolled Asthma

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Tiotropium Bromide Gel for Patients with Severe Hand Sweating

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Asthma Control and Adherence with Mepolizumab in Pre-filled Devices for Patients with Asthma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Tiotropium Bromide Monohydrate: A long-acting bronchodilator medication used to treat respiratory conditions by relaxing and opening the airways.
  • Pharmacokinetic: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Bronchodilator: A type of medication that relaxes the muscles around the airways, making it easier to breathe.
  • COPD: Chronic Obstructive Pulmonary Disease, a group of lung diseases that cause airflow blockage and breathing-related problems.
  • Easyhaler: A dry powder inhaler device used to deliver respiratory medications.
  • HandiHaler: A specific type of dry powder inhaler used to deliver tiotropium bromide.
  • Respimat: A soft mist inhaler that delivers a fine, slow-moving mist of medication.
  • Peak plasma concentration (Cmax): The highest concentration of a drug in the blood plasma after administration.
  • Area under the curve (AUC): A measure of the total exposure to a drug over time, used in pharmacokinetic studies.
  • Exacerbation: A worsening of symptoms or an acute episode in a chronic disease, such as COPD.
  • FeNO: Fractional exhaled nitric oxide, a measure of airway inflammation used in asthma assessment.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function used to assess the severity of obstructive lung diseases.
  • Clinical COPD Questionnaire (CCQ): A standardized questionnaire used to assess the impact of treatment on health status in COPD patients.

References

  1. https://clinicaltrials.gov/study/NCT03400241
  2. https://clinicaltrials.gov/study/NCT04850144
  3. https://clinicaltrials.gov/study/NCT05246046
  4. https://clinicaltrials.gov/study/NCT04648813
  5. https://clinicaltrials.gov/study/NCT01937390